<?xml version='1.0' encoding='utf-8'?>
<document id="26425918"><sentence text="Chiral Inhibition of Rivaroxaban Derivatives Towards UDP-Glucuronosyltransferase (UGT) Isoforms."><entity charOffset="21-32" id="DDI-PubMed.26425918.s1.e0" text="Rivaroxaban" /></sentence><sentence text="Rivaroxaban is an oral direct factor Xa (FXa) inhibitor clinically used to prevent and treat thromboembolic disorders"><entity charOffset="0-11" id="DDI-PubMed.26425918.s2.e0" text="Rivaroxaban" /></sentence><sentence text=" Drug-drug interaction (DDI) exist for rivaroxaban and the inhibitors of CYP3A4/5"><entity charOffset="39-50" id="DDI-PubMed.26425918.s3.e0" text="rivaroxaban" /></sentence><sentence text=" This study aims to investigate the inhibition of rivaroxaban and its derivatives with a chiral center towards UDP-glucuronosyltransferases (UGTs)"><entity charOffset="50-61" id="DDI-PubMed.26425918.s4.e0" text="rivaroxaban" /></sentence><sentence text=" Chemical synthesis was performed to obtain rivaroxaban derivatives with different chiral centers"><entity charOffset="44-55" id="DDI-PubMed.26425918.s5.e0" text="rivaroxaban" /></sentence><sentence text=" UGTs supersomes-catalyzed 4-methylumbelliferone (4-MU) glucuronidation was employed to evaluate the inhibition potential towards various UGT isoforms"><entity charOffset="27-48" id="DDI-PubMed.26425918.s6.e0" text="4-methylumbelliferone" /><entity charOffset="50-54" id="DDI-PubMed.26425918.s6.e1" text="4-MU" /><pair ddi="false" e1="DDI-PubMed.26425918.s6.e0" e2="DDI-PubMed.26425918.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26425918.s6.e0" e2="DDI-PubMed.26425918.s6.e1" /></sentence><sentence text=" A significant influence of rivaroxaban derivatives towards UGT1A3 was observed"><entity charOffset="28-39" id="DDI-PubMed.26425918.s7.e0" text="rivaroxaban" /></sentence><sentence text=" Chiral centers produce different effects towards the effect of four pairs of rivaroxaban derivatives towards UGT1A3 activity, with stronger inhibition potential of S1 than R1, but stronger inhibition capability of R2, R3, R4 than S2, S3, and S4"><entity charOffset="78-89" id="DDI-PubMed.26425918.s8.e0" text="rivaroxaban" /></sentence><sentence text=" Competitive inhibition of R3 and R4 towards UGT1A3 was demonstrated by Dixon and Lineweaver-Burk plots" /><sentence text=" In conclusion, the significant influence of rivaroxaban derivatives towards UGT1A3's activity was demonstrated in the present study"><entity charOffset="45-56" id="DDI-PubMed.26425918.s10.e0" text="rivaroxaban" /></sentence><sentence text=" The chirality centers highly affected the inhibition behavior of rivaroxaban derivatives towards UGT1A3"><entity charOffset="66-77" id="DDI-PubMed.26425918.s11.e0" text="rivaroxaban" /></sentence><sentence text="" /></document>